製品名:3,5-Bis(trifluoromethyl)benzyl Alcohol

IUPAC Name:[3,5-bis(trifluoromethyl)phenyl]methanol

CAS番号:32707-89-4
分子式:C9H6F6O
純度:98%
カタログ番号:CM115974
分子量:244.14

包装単位 有効在庫 価格(USD) 数量
CM115974-100g in stock ŢǤ
CM115974-500g in stock ǵǤǵ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:32707-89-4
分子式:C9H6F6O
融点:-
SMILESコード:FC(C1=CC(C(F)(F)F)=CC(CO)=C1)(F)F
密度:
カタログ番号:CM115974
分子量:244.14
沸点:173.9°C at 760 mmHg
MDL番号:MFCD00009907
保管方法:Store at room temperature.

Category Infos

Fluorinated Compounds
Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.

Column Infos

Alcohols
Alcohol is a type of organic compound that carries at least one hydroxyl ( −OH) functional group bound to a saturated carbon atom.
Tradipitant
Vanda announced that the FDA has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. If approved, tradipitant will be the first novel drug to be approved by the FDA for the treatment of gastroparesis in over 40 years and to be accepted for review by the FDA for gastroparesis in over 30 years. Tradipitant is an NK-1R antagonist. It works by blocking substance P, a small signaling molecule. Tradipitant can affect gastric peristalsis and directly affect neurotransmission in the brain area responsible for nausea and vomiting, thus playing a role in the treatment of symptoms of gastroparesis. This NDA is mainly based on the results of the Phase II VP-VLY-686-2301 study and the Phase III VP-VLY-686-3301 study.

Related Products